Show simple item record

dc.contributor.authorCorrea Paz, Clara
dc.contributor.authorSilva Candal, Andrés da
dc.contributor.authorPolo Tobajas, Ester
dc.contributor.authorParcq, Jerome
dc.contributor.authorVivien, Denis
dc.contributor.authorMaysinger, Dusica
dc.contributor.authorPelaz García, Beatriz
dc.contributor.authorCampos Pérez, Francisco
dc.date.accessioned2021-05-21T11:53:26Z
dc.date.available2021-05-21T11:53:26Z
dc.date.issued2021
dc.identifier.citationPharmaceutics 2021, 13(5), 757; https://doi.org/10.3390/pharmaceutics13050757
dc.identifier.urihttp://hdl.handle.net/10347/26254
dc.description.abstractIschemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapies
dc.description.sponsorshipThis project was supported by the FRQS, ISCIII (AC19/00031 and AC20/00041), and ANR under the framework of EuroNanoMed III_2020 (PLATMED_project); the European Union program FEDER and the European Regional Development Fund–ERDF; and the Xunta de Galicia (IN607D2020/03 and ED431G2019/03). E.P. and B.P acknowledge the AEI grants (PID2019-111218RB-I00 and RyC-2017-23457). Finally, F.C. thanks the ISCIII and Miguel Servet program (CPII19/00020)
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RYC-2017-23457/ES
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCell tracking
dc.subjectDiagnosis
dc.subjectDrug carriers
dc.subjectDrug control release
dc.subjectNanomedicine
dc.subjectNeuroprotection
dc.subjectRecovery
dc.subjectStroke
dc.subjectTissue plasminogen activator
dc.titleNew Approaches in Nanomedicine for Ischemic Stroke
dc.typeinfo:eu-repo/semantics/article
dc.identifier.DOI10.3390/pharmaceutics13050757
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics13050757
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.e-issn1999-4923
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Física de Partículas
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Química Inorgánica
dc.description.peerreviewedSI


Files in this item

application/pdf
Name: 2021_pharmaceutics_correa_new.pdf
Size: 6.264 Mb
Format: PDF


Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)
Except where otherwise noted, this item's license is described as  © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)





Harvesters:Useful links:
Universidade de Santiago de Compostela | Teléfonos: +34 881 811 000 e +34 982 820 000 | Contact Us | Send Feedback